Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients

doi:10.1111/1759-7714.14046

	Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients
	Gong, Lei 1,2; He, Ronghui 7; Xu, Yanjun 1,2; Luo, Taobo 1,6; Jin, Kaixiu 7; Yuan, Wuzhou 5; Zheng, Zengguang 1,4; Liu, Lanxuan 7; Liang, Zebin 7; Li, Ao 5
刊名	THORACIC CANCER
	2021-06-15
关键词	biomarker neoantigen load NSCLC prognosis whole exome sequencing
ISSN号	1759-7706
DOI	10.1111/1759-7714.14046
通讯作者	Zheng, Zhiguo(zhengzg@zjcc.org.cn) ; Li, Hui(11118029@zju.edu.cn)
英文摘要	Background The prognosis for patients with stage II/III non-small cell lung cancer (NSCLC) is unsatisfactory, even after complete tumor resection and adjuvant chemotherapy. Here, we assessed the prognostic and predictive value of immunogenomic signatures for stage II/III NSCLC in Chinese patients. Methods A total of 91 paired resected stage II/III NSCLC and normal tissues, including 47 squamous cell lung carcinomas (SCC) and 44 lung adenocarcinomas (ADC), were collected and analyzed using whole exome sequencing (WES) to identify immunogenomic signatures for association with clinicopathological variables and disease-free survival (DFS). Results Higher neoantigen load (NAL, >2 neoantigens/Mb) exhibited better DFS for SCC patients (p = 0.021) but not ADC patients. A benefit from adjuvant chemotherapy was correlated with lower NAL (<= 2 neoantigens/Mb) (p = 0.009). However, tumor mutation burden (TMB), mutations of individual gene, oncogene pathways, and antigen presentation machinery genes, and human leukocyte antigen (HLA)-I number and HLA-I loss of heterozygosity (LOH) had no prognostic or predictive value for DFS of SCC or ADC patients. Conclusions NAL is a useful biomarker for lung SCC prognosis and prediction of chemotherapy responses in Chinese patients. The predictive value of NAL for adjuvant immunotherapy should be further explored in patients with resected NSCLC.
资助项目	Natural Science Foundation of Zhejiang Province[LQ21H160004] ; Zhejiang Medical technology program[202143913]
WOS关键词	TUMOR ; BURDEN
WOS研究方向	Oncology ; Respiratory System
语种	英语
出版者	WILEY
WOS记录号	WOS:000661389300001
资助机构	Natural Science Foundation of Zhejiang Province ; Zhejiang Medical technology program
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/123772]
专题	中国科学院合肥物质科学研究院
通讯作者	Zheng, Zhiguo; Li, Hui
作者单位	1.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou 310022, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol, Hangzhou 310022, Peoples R China 3.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Zhejiang Canc Res Inst, Hangzhou 310022, Peoples R China 4.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Pathol, Hangzhou, Peoples R China 5.Mingma Technol Co Ltd, Shanghai, Peoples R China 6.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Thorac Surg, Hangzhou, Peoples R China 7.Hangzhou YITU Healthcare Technol Co Ltd, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Gong, Lei,He, Ronghui,Xu, Yanjun,et al. Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients[J]. THORACIC CANCER,2021.
APA	Gong, Lei.,He, Ronghui.,Xu, Yanjun.,Luo, Taobo.,Jin, Kaixiu.,...&Li, Hui.(2021).Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients.THORACIC CANCER.
MLA	Gong, Lei,et al."Neoantigen load as a prognostic and predictive marker for stage II/III non-small cell lung cancer in Chinese patients".THORACIC CANCER (2021).